Testbed Sweden and Health Policy Network have developed a framework to help researchers design and run trials that support the integration of precision cancer medicine in practice.

The Lung Cancer Association, in collaboration with the Zero Vision Cancer and All.Can Sweden, hosted a webinar discussing the future of lung cancer screening.

Welcome to a webinar about Molecular Tumour Board Portal – decision support system for omics data in cancer treatment and clinical studies. The Molecular Tumor Board Portal (MTBP) has been developed within Janne Lehtiö's lab at Karolinska Institutet and serves as a decision support system for patient inclusion in the Basket of Baskets (BoB) study, conducted as part of the Cancer Core Europe collaboration.

Lung cancer is the deadliest form of cancer in terms of number of deaths in Sweden, yet a national screening program is still lacking. A new report from IHE - The Swedish Institute for Health Economics, commissioned by Vision Zero Cancer and AstraZeneca, shows that AI can reduce the resource need and costs for radiologists by approximately 80% and enable earlier detection.

The report has been developed as a part of IHE’s partnership in the VINNOVA-funded innovation milieu Test Bed Sweden Precision Health Cancer.

Together with Lif - de forskande läkemedelsföretagen, Business Sweden, Embassy of Sweden in Madrid, Spain, we arranged for the second consecutive year a special evening event during the ESMO congress.

Cancer is a global societal challenge. To meet it, we need to create better conditions for implementing new knowledge, new methods, and interventions. We need to think anew and adopt a holistic perspective on health. We need to collaborate in new ways between healthcare, industry, and civil society.

The development of precision medicine has been ongoing since the 1990s. From treatments for a few patients, we are today faced with the widespread introduction of precision medicine in new parts of healthcare.

On April 23rd-24th, Vision Zero Cancer/ SIR will be at the Nordic Precision Medicine Forum in Stockholm and organise a workshop on impact assessment frameworks for Precision Medicine implementation.

The lung cancer policy network speaks to Ebba Hallersjö Hult, Co-founder and Head of Vision Zero Cancer, a mission-oriented innovation hub coordinated by Stockholm School of Economics Institute for Research, Sweden.

Folkhälsodalen (The Public Health Valley) is a meeting place for decision-makers, professionals, industry, and researchers in public health, medicine, and healthcare. An initiative of Reform Society. The seminars are in Swedish.

House of Innovation in collaboration with the Department of Accounting at Stockholm School of Economics orgianizes two Workshops on Measuring Impact of Mission Driven Innovation Collaborations during this fall.

A Public-Private Partnership focusing on implementation of precision health in cancer in Sweden is under establishment. SweConnect will be project managed by Vision Zero Cancer in collaboration with Genomic Medicine Sweden (GMS).

Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?

The PRIME-ROSE kick-off took place in Oslo on September 19-20 and gathered around 70 participants from different partners across Europe.

Testbed Sweden Precision Cancer is attending the PRIME-ROSE kick-off in Oslo right now!

We are looking forward to participating at the Nordic Precision Cancer Medicine conference in Oslo during next week.

FOCU.SE is an initiative by Testbed Sweden Precision Health Cancer, founded by Vision Zero Cancer, Genomic Medicine Sweden and SciLifeLab, involving regulators, policymakers, payers, researchers, healthcare providers, patient advocates, and industry to drive the implementation of precision health in cancer care.

Testbed Sweden for Precision Health in Cancer is a system demonstrator of how to introduce concrete precision medicine activities into the Swedish healthcare system in a way that is sustainable and just.